Skip to main content
NOW YOU MAY BE ABLE TO START WITH SCEMBLIX

As of October 2024, SCEMBLIX is now approved for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Ask your doctor if SCEMBLIX may be right for you.

The approval of SCEMBLIX in patients newly diagnosed is based on a study that measured major molecular response (MMR) rate. There are ongoing studies to confirm the clinical benefit of SCEMBLIX for this use and how SCEMBLIX works over a longer period of time.

SCEMBLIX® is for those whose journey has had its ups and downs

ANYTHING BUT
A STRAIGHT LINE

SCEMBLIX is for those whose journey has had its ups and downs

Switching to SCEMBLIX?

Learn why some patients who haven't responded to 2 or more TKIs are asking their doctor about SCEMBLIX.

Ph+ CML-CP With T315I Mutation?

Find out why your doctor may order a test to determine whether you have the T315I gene mutation and how SCEMBLIX may help.